Abbott receives CE mark for next generation CL disinfection solution

Article

A new disinfecting technology for soft contact lenses from Abbott has received European regulatory approval. Complete RevitaLens Multipurpose Disinfecting Solution was developed in partnership with the Holden Vision Institute.

A new disinfecting technology for soft contact lenses from Abbott has received European regulatory approval. Complete RevitaLens Multipurpose Disinfecting Solution was developed in partnership with the Holden Vision Institute, which also helped to develop Silicone Hydrogel lenses.

“This advanced, next-generation solution establishes a new standard of disinfecting technology for contact lens wearers,” said Jim Mazzo, senior vice president, Abbott Medical Optics. “ Proper contact lens care, including a rub and rinse regimen using Complete RevitaLens Multipurpose Disinfecting Solution, will help patients achieve clean and comfortable lenses, extended wear times, and overall enhanced lens- wearing satisfaction. ”

Abbott plans to begin shipment of Complete RevitaLens Multipurpose Disinfecting Solution in select European markets this June with a full commercial launch in Europe by year end.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.